Table 2.

IC₅₀ data for pyrrolo[4,3,2-de]quinolines and therapeutic standards against ovarian and pancreatic cancer tumor cell lines.

Compound	PANC-1	OVCAR-3/-5
	IC50 (μM)
makaluvamine A (1)	0.45
makaluvamine C (2)	0.73	0.24 a/NT
damirone B (3)	19
makaluvamine H (4)	3.6	0.96 a/0.10 a
damirone A (5)	160
damirone D (6)	3.4
makaluvamine D (7)	0.29
makaluvamine G (8)	6.2
makaluvamine J (9)	0.054	NT/0.12
makaluvamine K (10)	0.56
makaluvamine L (11)	1.9
makaluvamine P (12)	0.3
9-N-acetyl makaluvamine B (14)	91
15-O-acetyl makaluvamine J (15)	0.081	NT/0.0086
8,15-O-diacetyl-8-hydroxy-5a,7,8a-trien-makaluvamine J (16)	0.59
ammosamide B (17)	26
FBA-TBQ (18)	0.11 b	0.95 c/NT
isobatzelline C (19)	10 d
discorhabdin C (20)	NT	0.33 e/2.6 e
etoposide	0.39
teniposide	0.041
gemcitabine	7.2 f

NT = Not Tested; Refs: ^a data obtained from Dijoux et al. [9]; ^b data obtained from Zhang et al. [25]; ^c data obtained from Chen et al. [31]; ^d data obtained from Guzmán et al. [26]; ^e data obtained from the NCI-DTP 60 Human Tumor Cell Lines Database; ^f data obtained from Li et al. [30].